Generic Name and Formulations:
Aminolevulinic acid HCl 10%; gel; contains isopropyl alcohol.
Indications for AMELUZ:
In combination with photodynamic therapy (PDT) using BF-RhodoLED lamp (red light illumination source), for the treatment of mild-to-moderate actinic keratoses on the face and scalp.
Clean and prepare all lesions prior to application. Apply gel approx. 1mm thick and include approx. 5mm of the surrounding skin. Use sufficient amount of gel to cover lesion(s) and entire area. Max application area of 20cm2 and max 2g (1 tube) use at one time. Cover treated area with occlusive dressing for 3 hours, then remove dressing and any remaining gel; immediately following illumination with red light: see full labeling. Treated lesions not completely resolved after 12 weeks may be retreated.
<18yrs: not established.
Porphyrin hypersensitivity. Porphyria. Photodermatoses.
Administered by healthcare provider only. In combination with PDT may cause transient amnestic episodes. Not for ophthalmic, oral, or intravaginal use. Avoid sunlight, prolonged, or intense light (eg, tanning beds, sunlamps) on lesions and surrounding skin for 2 days after treatment. Avoid applying to eyes, mucous membranes. Inherited or acquired coagulation disorders. Pregnancy. Nursing mothers.
May increase risk of phototoxic reaction to PDT with concomitant other photosensitizing agents (eg, St. John's wort, griseofulvin, thiazides, sulfonylureas, phenothiazines, sulfonamides, quinolones, tetracyclines).
Application site erythema, pain/burning, irritation, edema, pruritus, exfoliation, scab, induration, vesicles, paresthesia, hyperalgesia; ophthalmic reactions, increased photosensitivity.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|